RxDoctor Payments Data

Daniel Ng, MD

Colon & Rectal Surgery · Newport Beach, CANPI 1265523351

Payments from drug & device makers

What this record shows

This record is dominated by education: $7,000 of the $10,189 with a category attached, or 68.7%. Intuitive Surgical accounts for 88.1% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $8,219 and has fallen 98.2% since, to $152 in 2025.

$10,189in general payments, 2019–2025

Across 58 payments — averaging $175.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$9K
  • Braintree Laboratories, Inc.$690
  • Davol Inc.$98
  • Merck$92
  • Lilly USA, LLC$89
  • Sanofi$56
  • plus $193 from 8 others

What the payments were for

  • Travel & lodging$1,45514%
  • Food & beverage$1,12111%
  • Education$7,00069%
  • Gifts$6136%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,189 in reported general payments places this provider in the 70th percentile of 176 colon & rectal surgery providers in California.

See all colon & rectal surgery providers in California

Medicare billing

Part B allowed, 2024
$262,394
Medicare patients
585
Services billed
1,639

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SutabSod Sulf/Pot Chloride/Mag Sulf24$3,667
ErythromycinErythromycin Base30$1,145
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates16$1,078
Potassium Chloride184$350
Neomycin Sulfate30$163
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$81
Prochlorperazine Maleate29$50

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Braintree Laboratories, Inc.Sutab$690$3,66724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 176 colon & rectal surgery providers in California.

Other colon & rectal surgery in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →